Clinical trial · Interventional
Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The parents of two patients enrolled who died, presented a claim against the hospital and the study was halted.
Summary
Brief summary (as posted)
The investigators propose a new antitumor cell therapy for treating childhood refractory solid tumours. The aim of this study is explore the graft versus tumour effect mediated by allogenic natural killer cells (NKs). NK cell alloreactivity can be predicted by donor killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I alleles mismatch. Cells without an inhibitory HLA ligand may trigger natural killer cell activation and elimination of those target cells. Reduced risk of relapsed has been described in malignant cancer after haploidentical stem cell transplantation when HLA ligands against the inhibitory KIRs present in the donor were absent in the recipient (KIR-HLA receptor-ligand mismatch). NK alloreactivity could also be obtained by Natural Killer Receptor (NCR), Toll-Like-Receptors (TLRs) and NKG2D receptor stimulation mediated by cytokines or tumour cell lines. This will be an open, non randomized, Phase I/II clinical trial, with a double objective: therapeutic exploratory. The investigators aim at studying safety and efficacy of haploidentical stem cell transplantation for the treatment of these malignancies with no cure known. Patients will receive an haploidentical stem cell transplantation, followed by IL-15 stimulated NK cells infusion one month after transplantation. Efficacy of the procedure will be evaluated with up-to-date radiological techniques, molecular studies and functional assays.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Solid Tumor | Childhood Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HAPLOIDENTICAL IL-15 STIMULATED NK CELLS | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IL-15 STIMULATED NK CELLS
- interventionNames
- Other: HAPLOIDENTICAL IL-15 STIMULATED NK CELLS
Primary outcomes (1)
- measure
- Number of patients with adverse events according to NCI-CTC v3.0 CRITERIA as a measure of safety and tolerability
- timeFrame
- Up To 1 Year After Transplantation
Secondary outcomes (1)
- measure
- Objective Response Rate According RECIST V1.1
- timeFrame
- Up To One Year After Transplantation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
- Maximum age
- 22 Years
Show eligibility criteria text
Inclusion Criteria: * Age 6 months to 22 years. * Histological solid tumor confirmation. * Measurable solid tumor by image or molecular techniques. * Solid tumors that have failed to at least 2 chemotherapy protocols. * Suitable haploidentical donor available. * Lansky score \> 60%. Exclusion Criteria: * Serum bilirubin \> 3 mg/dl * GFR \< 40 ml/min/1.73 mw * Cardiac left ventricular ejection fraction \< 40% * HIV+ * Pregnant * Unfavorable psycho-social report. * Antecedent of abandonment treatment.
References
Publications (1)
- BACKGROUNDPerez-Martinez A, Leung W, Munoz E, Iyengar R, Ramirez M, Vicario JL, Lassaletta A, Sevilla J, Gonzalez-Vicent M, Madero L, Diaz-Perez MA. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer. 2009 Jul;53(1):120-4. doi: 10.1002/pbc.21955. PMID 19215002